Perfluorocarbon oxygen carrier Due Diligence Report 2026

This Perfluorocarbon oxygen carrier Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Perfluorocarbon oxygen carrier can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Perfluorocarbon oxygen carrier (query alias: Perfluorocarbon oxygen carrier)
Modality / target	Small molecule drug; Not disclosed; Oxygen carriers
Highest global status	Phase 2
Originator	Tenax Therapeutics, Inc.
Active developers	Aurum Biosciences Ltd.

The MCP disease footprint includes Inflammation, Stroke, Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06850324	Phase 2	Not yet recruiting	18	Primary endpoint not disclosed in English source
CTRI/2024/10/075127	Not Applicable	Completed	30	Primary endpoint not disclosed in English source
NCT03463551	Phase 2	Unknown status	18	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002

Phase 2; n=9; evaluation: Not stated in English source. Reported fields: brain dialysate glucose concentration(Mean) = 800 microM/L

Perfluorocarbon liquid use during vitrectomy for macula-Off Retinal detachment has no impact on Macular folds and Metamorphopsia

Not Applicable; n=not disclosed; evaluation: Not stated in English source. Reported fields: BCVA = 0.15 LogMAR

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Perfluorocarbon oxygen carrier addresses Inflammation, Stroke, Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-11-28	WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies	Not disclosed	US$220.0M stated total
2012-02-01	Oxygen Biotherapeutics and Aurum Biosciences Enter Joint Research Agreement to Develop an Oxycyte(R)-Based Diagnostic Tool and Therapeutic for Acute Ischemic Stroke	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons”. The milestone feed surfaced a patent-application signal described as “Perfluoro Compounds For Use In Imaging”. The milestone feed surfaced a patent-application signal described as “Emulsions of perfluorocarbons”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO